title: The novel thromboxane A2 receptor antagonist KW-3635 abolishes the cyclic flow reduction in the canine carotid artery.
abstract: We tested the hypothesis that the abolition of the cyclic flow reduction (CFR) in the canine carotid artery is related to inhibition of ex vivo platelet aggregation following administration of KW-3635, a thromboxane A2 receptor antagonist, or aspirin. The CFR was induced in the carotid artery of anesthetized dogs by mechanical injury and narrowing of the artery. After induction of CFR, KW-3635 or aspirin was administered every 30 min at doses of 0,1,0.3, 1 and 3 mg/kg (i.v.). The ex vivo platelet aggregation, induced by sodium arachidonate and collagen, was also examined before and 15 min after each administration. KW-3635 and aspirin, at doses of 1 mg/kg i.v. and above, inhibited CFR and ex vivo platelet aggregation. These results that CFR in the canine carotid artery is platelet-dependent.
authors.affiliation: Department of Pharmacology, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Higo
authors.forename: A
authors.initials: A
authors.lastname: Karasawa
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology*; D001584:Benzoxepins / Q000494:pharmacology*; D002339:Carotid Arteries / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors*; D012039:Regional Blood Flow / Q000187:drug effects; D013928:Thromboxane A2 / Q000502:physiology
chemical_list: D001562:Benzimidazoles; D001584:Benzoxepins; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; D001241:Aspirin; C065729:KW 3635